# Investment Decision Report: HealthBridge AI Inc.

**Generated:** 2026-01-12 20:23 UTC
**Report ID:** `report_ff4e526bbf9b`

---

## Table of Contents

1. [Executive Summary](#1-executive-summary)
2. [Inferred Decision Logic](#2-inferred-decision-logic)
3. [Evidence Basis](#3-evidence-basis)
4. [Deal Evaluation](#4-deal-evaluation)
5. [Counterfactual & Sensitivity Analysis](#5-counterfactual--sensitivity-analysis)
6. [Uncertainty & Limitations](#6-uncertainty--limitations)
7. [Audit Metadata](#7-audit-metadata)

## 1. Executive Summary

### Decision: **DEFER**

**Confidence:** 50% (low)

> Recommend DEFER decision on HealthBridge AI Inc. pending additional due diligence (50% confidence).

### Key Strengths
- traction: pilot_clinics (3)
- traction: physician_nps (72)
- traction: diagnoses_assisted (15000)
- team_quality: founder_background (MIT CS PhD, 8 years ML at Apple Health)
- product_readiness: stage (production)

### Key Risks
- execution_risk: domain_expertise_gap (No full-time clinical leadership; advisors part-time)
- regulatory_risk: clearance_timeline (12-18 months estimated)
- business_model: sales_cycle (6-9 months average)
- differentiation: competitors (Nuance (Microsoft), Isabel Healthcare, Infermedica)
- execution_risk: competitive_threat (Microsoft Nuance has 500x resources; unclear differentiation path)

### Critical Uncertainties
None identified

### Recommendation

The evidence is insufficient to make a definitive investment decision (50% confidence). DISCLAIMER: This is decision support only, not investment advice. Final investment decisions remain the responsibility of the investment committee.

## 2. Inferred Decision Logic

**Net Signal Score:** +5.82

### Decision Threshold
Net signal score (5.82) is in the uncertain zone. Neither clear invest nor pass criteria are met.

### Rule Evaluations

| Rule | Result | Weight |
|------|--------|--------|
| Traction Assessment | PASS | 40% |
| Team Assessment | PASS | 30% |
| Market Assessment | PASS | 20% |
| Business Model Assessment | PARTIAL | 30% |
| Risk Assessment | FAIL | 50% |
| Technical Assessment | PASS | 20% |

### Decision Rationale
The decision to DEFER reflects insufficient evidence or high uncertainty (net signal: 5.82, 31 claims). Additional due diligence is recommended before making a final determination.

## 3. Evidence Basis

- **Total Claims:** 31
- **Supportive:** 12
- **Risk:** 5
- **Neutral:** 14
- **Average Confidence:** 82%

### Supportive Evidence

| Type | Field | Value | Confidence |
|------|-------|-------|------------|
| traction | pilot_clinics | 3 | 90% |
| traction | physician_nps | 72 | 80% |
| traction | diagnoses_assisted | 15000 | 85% |
| team_quality | founder_background | MIT CS PhD, 8 years ML at Appl | 92% |
| product_readiness | stage | production | 90% |

### Risk Evidence

| Type | Field | Value | Confidence |
|------|-------|-------|------------|
| execution_risk | domain_expertise_gap | No full-time clinical leadersh | 80% |
| regulatory_risk | clearance_timeline | 12-18 months estimated | 60% |
| business_model | sales_cycle | 6-9 months average | 75% |
| differentiation | competitors | Nuance (Microsoft), Isabel Hea | 85% |
| execution_risk | competitive_threat | Microsoft Nuance has 500x reso | 70% |

## 4. Deal Evaluation

- **Company:** HealthBridge AI Inc.
- **Company ID:** `healthbridge-2024`
- **Sector:** Not specified
- **Stage:** Not specified

### Traction
arr: 180000; pilot_clinics: 3; physician_nps: 72

### Team
founder_background: MIT CS PhD, 8 years ML at Apple Health; team_size: 12; clinical_advisors: 2

### Market
tam: 12000000000; market_timing: Post-COVID telehealth adoption accelerating AI interest

### Risks
domain_expertise_gap: No full-time clinical leadership; advisors part-time; fda_status: Pre-submission meeting scheduled; Class II 510(k) pathway; clearance_timeline: 12-18 months estimated

## 5. Counterfactual & Sensitivity Analysis

- **Robustness Score:** 100%
- **Stability Margin:** 100%
- **Counterfactuals Tested:** 20
- **Flips Found:** 0

### Interpretation
The decision is highly stable with a robustness score of 100%. 0 of 20 counterfactuals (0%) resulted in decision flips. The decision is robust to most reasonable changes in evidence.

### Critical Claims
No critical claims identified.

## 6. Uncertainty & Limitations

- **Epistemic Uncertainty:** 20% (reducible)
- **Aleatoric Uncertainty:** 15% (irreducible)
- **Confidence Level:** MEDIUM

### Data Gaps
- Limited evidence for team quality (only 1 claim)

### Recommendations for Due Diligence
- Standard due diligence processes recommended

### Limitations
- This analysis is decision support only, not investment advice
- Confidence scores reflect model uncertainty, not success probability
- Analysis is based solely on provided evidence
- External factors not in evidence graph are not considered

## 7. Audit Metadata

| Field | Value |
|-------|-------|
| Report ID | `report_ff4e526bbf9b` |
| Generated At | 2026-01-12 20:23:54 UTC |
| Model Version | 1.0.0 |
| Trace ID | `N/A` |
| Analyst ID | N/A |
| Claims Analyzed | 31 |
| Counterfactuals Tested | 20 |
| Reproducibility Seed | 42 |

---

## Disclaimer

**IMPORTANT:** This report is decision support only, not investment advice.
All investment decisions remain the sole responsibility of the investment committee.
Confidence scores reflect model uncertainty, not probability of investment success.

---

*Generated by JURIS-AGI VC Decision Intelligence*